The delegation included Dr. Antonio Werneck, President of Instituto Vital Brazil, Dr. Augusto Raupp, President of the Research Foundation of the State of Rio de Janeiro (FAPERJ), Dr. Joao Transmontano, CEO of Biolotus Biotech, and Mr.Alexandre Sergio Alves Vieira, Undersecretary of State, Science, Technology, and Innovation, and Dr. Lélio Maiçara, President of Laborvida.
Brazil has become an increasingly attractive target for biosimilar developers such as JHL because the government strongly supports its domestic manufacturers in working with international partners.
Racho Jordanov, President and CEO of JHL Biotech, said, “The Brazilian market is a vital part of JHL Biotechs global commitment to making world-class biopharmaceuticals affordable to all patients. We are excited and privileged to work with our Brazilian partners to make quality medicines affordable for more people.”
“JHL Biotech has an impressive quality line-up of biosimilars under development,” said Dr. Joao Transmontano, CEO of Biolotus Biotech. “Together with Biolotus extensive know-how in pharmaceutical development of biologics, registration and international market penetration, we foresee a strategic partnership to serve the biologic pharmaceutical needs of the Brazilian people and global community.”
The delegation toured JHLs state-of-the-art research and manufacturing facilities, which have been rapidly expanded in the last year to include dedicated formulation and molecular cell biology laboratories. The delegation also had the opportunity to observe GMP production activities in JHLs cGMP manufacturing plant, which earlier this year successfully released its first CMO drug substance batch in Taiwan and passed Australian inspection. The Taiwan plant complements JHLs “big brother” cGMP facility in Wuhan, China, which when completed in 2015, will be the largest mammalian manufacturing plant of its kind in China.
More Information on World News Report